Ask AI

InterACT Oncology Team Training: Overcoming Clinical Challenges to Maximize Patient Benefit from Adjuvant CDK4/6 Inhibitors for High-Risk HR-positive/HER2-negative Early Breast Cancer

Gain expert insights into adjuvant CDK4/6 inhibitor–based therapy for high-risk HR-positive/HER2-negative early breast cancer (EBC) to optimize adherence and toxicity management and maximize therapeutic benefits through a certified on-demand webcast, expert-written ClinicalThought commentary, downloadable resource, and downloadable slides.

Share

Program Content

Activities

Adjuvant CDK46i for EBC
Maximizing Patient Benefit With Adjuvant CDK4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 28, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC, in partnership with Smart Patients.

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner